The litigation, filed in the U.S. District Court for the Northern District of California, accuses PROCEPT and its top executives of violating the Securities Exchange Act of 1934. According to the complaint, the company utilized a discount strategy that pulled forward sales, resulting in a glut of over 10,000 excess units in field inventory by the end of the class period. These actions allegedly caused the company to issue guidance that lacked a factual basis, leading to significant stock price drops when the discrepancies between unit sales and actual clinical procedures were revealed.
In section Releases
Investors Face September 22 Deadline in PROCEPT BioRobotics Class Action
Investors who purchased PROCEPT BioRobotics common stock between February 28, 2024, and February 25, 2026, have until September 22, 2026, to seek appointment as lead plaintiff. The class action lawsuit alleges the company artificially inflated revenue through undisclosed discount programs that incentivized bulk orders exceeding actual procedure demand.
Financial disclosures throughout 2025 and early 2026 underscored the impact of this inventory mismanagement. Following reports of missed sales targets and the elimination of the Chief Commercial Officer role, PROCEPT shares experienced repeated declines. By February 2026, the company confirmed that handpiece sales had consistently outpaced procedures since early 2023, culminating in a 30% sequential decline in quarterly sales. Investors seeking to participate in the lawsuit or serve as lead plaintiff may contact Robbins Geller Rudman & Dowd LLP to review the case details.
Comments (0)
No comments yet. Be the first!